NeuroSense advances ALS drug commercialization in Canada

NeuroSense Therapeutics Ltd. is making progress toward selling its ALS drug, PrimeC, in Canada. The company announced that Health Canada is inviting them to a meeting to discuss regulatory approval. They aim to secure this approval by the first half of 2026. If successful, they estimate annual revenue in Canada could reach $100-150 million. PrimeC is NeuroSense's leading treatment for Amyotrophic Lateral Sclerosis (ALS). It is an oral drug that combines ciprofloxacin and celecoxib. Clinical trials have shown positive results, including a 36% slowdown in disease progression and a 43% improvement in survival compared to a placebo. In December 2024, NeuroSense received favorable feedback from the FDA on its Phase 3 trial design for PrimeC. They plan to start this important study in mid-2025. The company has also reached an agreement with a global pharmaceutical firm to support PrimeC's development, which includes initial payments and funding for further trials. The ALS treatment market has seen substantial financial deals recently, indicating strong investment in innovative therapies. Analysts on Wall Street continue to endorse NeuroSense, maintaining a Buy rating and setting a target price of $7.50, which is higher than its current stock price.